Cargando…
Efficacy of EGFR‐TKIs with or without upfront brain radiotherapy for EGFR‐mutant NSCLC patients with central nervous system metastases
BACKGROUND: Although the clinical efficacy of epidermal growth factor receptor tyrosine kinase inhibitors (EGFR‐TKIs) in EGFR‐mutant non‐small cell lung cancer (NSCLC) patients has been demonstrated, their efficacy in EGFR‐mutant NSCLCs with central nervous system (CNS) metastases and the role of ra...
Autores principales: | Saida, Yu, Watanabe, Satoshi, Abe, Tetsuya, Shoji, Satoshi, Nozaki, Koichiro, Ichikawa, Kosuke, Kondo, Rie, Koyama, Kenichi, Miura, Satoru, Tanaka, Hiroshi, Okajima, Masaaki, Terada, Masaki, Ishida, Takashi, Tsukada, Hiroki, Makino, Masato, Iwashima, Akira, Sato, Kazuhiro, Matsumoto, Naoya, Yoshizawa, Hirohisa, Kikuchi, Toshiaki |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley & Sons Australia, Ltd
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6825912/ https://www.ncbi.nlm.nih.gov/pubmed/31507098 http://dx.doi.org/10.1111/1759-7714.13189 |
Ejemplares similares
-
Observational study of rebiopsy in EGFR-TKI-resistant patients with EGFR mutation-positive advanced NSCLC
por: Koyama, Kenichi, et al.
Publicado: (2022) -
Combination of EGFR-TKIs with chemotherapy versus chemotherapy or EGFR-TKIs alone in advanced NSCLC patients with EGFR mutation
por: Wen, Miaomiao, et al.
Publicado: (2018) -
Microwave ablation combined with EGFR-TKIs versus only EGFR-TKIs in advanced NSCLC patients with EGFR-sensitive mutations
por: Wei, Zhigang, et al.
Publicado: (2017) -
Phase II study of nanoparticle albumin-bound paclitaxel monotherapy for relapsed non-small cell lung cancer with patient-reported outcomes (NLCTG1302)
por: Shoji, Satoshi, et al.
Publicado: (2022) -
DDX3X Induces Primary EGFR-TKI Resistance Based on Intratumor Heterogeneity in Lung Cancer Cells Harboring EGFR-Activating Mutations
por: Nozaki, Koichiro, et al.
Publicado: (2014)